Results: Zynex, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Earnings Call: Zynex Reports Steady Q3 Growth, Plans for Future Expansion
RBC Capital Maintains Zynex(ZYXI.US) With Buy Rating, Maintains Target Price $11
Zynex Analyst Ratings
H.C. Wainwright Maintains Zynex(ZYXI.US) With Buy Rating, Raises Target Price to $17
Zynex's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
Express News | Zynex, Inc. : H.c. Wainwright Raises Target Price to $17 From $16
Zynex, Inc. (ZYXI) Q3 2024 Earnings Call Transcript Summary
Zynex | 10-Q: Q3 2024 Earnings Report
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates
Zynex Sees Pain Management Orders Increase in Q3 Following FDA Approval | NASDAQ:ZYXI
Express News | Zynex Shares up 5.4% After the Bell Following Results
Express News | Zynex Inc Outlook Q4 Diluted EPS Is Estimated to Be at Least $0.09
Zynex Q3 2024 GAAP EPS $0.07 Beats $0.06 Estimate, Sales $49.966M Miss $50.827M Estimate
Express News | Zynex Outlook FY Revenue USD 200 Million
Express News | Zynex Q3 Adjusted Ebitda USD 5.1 Million
Press Release: Zynex Reports Third Quarter 2024 Financial Results
Zynex 3Q Rev $50M >ZYXI
Zynex 3Q EPS 7c >ZYXI
Here Are the Major Earnings After the Close Today